Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + letrozole in ER-positive HER2-negative metastatic breast cancer
2012-003065-17Phase 2Unknown
- Sponsor
- Novartis
- Start
- Feb 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and letrozole in breast cancer, sponsored by Novartis. Primary endpoint: Percentage of patients progression-free after completion of first-line treatment. Status: unknown.
02
Drugs
everolimusletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-003065-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003065-17.